Eli Lilly scored another win against diabetes as the company’s once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide won approval under Priority Review from the U.S. Food and Drug Administration.

AstraZeneca’s proposed treatment for heart disease delivered positive high-level results from the company’s Phase III DELIVER trial.

Rivus Pharmaceuticals, a biopharma company focused on therapies for cardiometabolic health, announced positive data from a Phase IIa clinical trial.

The Janssen Pharmaceutical (a Johnson & Johnson company) medicine Invokana (canagliflozin) has a list of safety warnings, including ketoacidosis, a severe complication of diabetes that is potentially life-threatening. According to an investigation conducted by Reuters, J&J knew of the risk of ketoacidosis, but covered it up.

The number of young people with the most prevalent form of diabetes nearly doubled in the United States from 2001 to 2017, according to a study published on Aug. 24.

The U.S. Food and Drug Administration approved Viatris and Biocon Biologics’ Semglee (insulin glargine-yfgn injection) as the first interchangeable biosimilar product, which is indicated to control high blood sugar in adults with Type 2 diabetes as well as adults and pediatric patients with Type 1 diabetes.

The United States Food and Drug Administration approved Bayer’s Kerendia (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist indicated to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death, non-fatal myocardial infarction and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes.

Eli Lilly’s investigational diabetes drug tirzepatide is showing significant promise in targeting A1C levels and weight loss in patients with type 2 diabetes, including those who had never been previously treated for the disease. In other positive clinical results presented at the American Diabetes Association’s 81st Scientific Sessions meeting, Novo Nordisk data demonstrated an investigational 2mg dose of injectable Ozempic (semaglutide) generated statistically significant and superior reductions in A1C compared to a 1mg dose of Ozempic.

AstraZeneca Plc’s diabetes drug significantly reduced blood sugar levels in adolescents aged 10–17 with type 2 diabetes in a late-stage study, the UK-based drugmaker said.

Newly announced topline results from Eli Lilly’s SURPASS-4 trial program show the company’s investigational diabetes agent, tirzepatide, significantly reduced blood glucose levels and body weight better than insulin glargine in adult patients with type 2 diabetes.